Patent Cliff Continues in 2014, But Not So Steeply
Executive Summary
Most of big pharma has crossed to the other side of the patent cliff and put their biggest losses behind them in 2012 and 2013, but a few major blockbusters will face new generic competition this year, including Nexium, Copaxone, and Nasonex.
You may also be interested in...
First Generic Approvals Decline For Fourth Straight Year At US FDA
Blemish in otherwise record-setting performance could simply be a result of coalescing variables, but it robs the agency of an easy pricing message.
First Generic Approvals Decline For Fourth Straight Year At US FDA
Blemish in otherwise record-setting performance could simply be a result of coalescing variables, but it robs the agency of an easy pricing message.
Lilly’s Late-Stage CNS Pipeline Bare Following Edivoxetine Failure
Depression candidate edivoxetine fails in three Phase III studies, marking a third recent blow to Lilly’s neuroscience pipeline efforts.